Monday, November 11, 2019

Inhibrx Abandons IPO Plans, For Now

La Jolla-based Inhibrx, a biopharmaceuticals developer which was focused on protein engineering technology, has filed to withdraw its IPO, saying it "does not intend to pursue the contemplated public offering at this time." The company--which had applied to list as INBX on the Nasdaq Global Market--had been seeking to raise up to $74.75M in its IPO. The

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.